Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events. METHODS: We randomly assigned 598...

Descripción completa

Detalles Bibliográficos
Autores principales: Packer, Milton, Butler, Javed, Zannad, Faiez, Filippatos, Gerasimos, Ferreira, Joao Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Schnaidt, Sven, Zeller, Cordula, Schnee, Janet M., Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522627/
https://www.ncbi.nlm.nih.gov/pubmed/34459213
http://dx.doi.org/10.1161/CIRCULATIONAHA.121.056824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522627/
https://www.ncbi.nlm.nih.gov/pubmed/34459213
http://dx.doi.org/10.1161/CIRCULATIONAHA.121.056824

Ejemplares similares